Etanercept and infliximab for rheumatoid arthritis
- 1 July 2001
- journal article
- research article
- Published by BMJ in Drug and Therapeutics Bulletin
- Vol. 39 (7) , 49-52
- https://doi.org/10.1136/dtb.2001.39749
Abstract
▼Etanercept* (Enbrel - Wyeth) and▼infliximab* (Remicade - Schering Plough) belong to a new class of drugs that block the effects of tumour necrosis factor-alpha (TNF-α), a mediator of inflammation. Both are licensed for the treatment of patients with active rheumatoid arthritis who have responded inadequately to disease-modifying antirheumatic drugs (DMARDs). Here, we consider whether etanercept and infliximab offer advantages.Keywords
This publication has 0 references indexed in Scilit: